

## Genetics Report


Patient details:

Sample details:

**Clinical Summary:** CML on second-line nilotinib for 2 years and 8 months. For *BCR-ABL1* monitoring by RT-qPCR.

### *BCR-ABL1* quantitative PCR (RT-qPCR) monitoring report (transcript type = e13a2/e14a2)

Treatment response	<i>BCR-ABL1:ABL1</i> % ratio on IS	MR level	Date next sample due
Optimal	0.080	MR <sup>3</sup>	January 2018



Reported by:

Authorised by:

Laboratory Number (Sample Type)	Date received	Copies of <i>BCR-ABL1</i>	Copies of <i>ABL1</i>	<i>BCR-ABL1:ABL1</i> ratio (IS)	<i>BCR-ABL1:ABL1</i> ratio on IS (%)	Sensitivity of detection (1/ <i>ABL1</i> )	Molecular Response (MR)
	28/08/2014	242,000	233,000	1.458	145.81	0.000004	--
	02/12/2014	15,000	69,000	0.296	29.61	0.000014	--
	20/01/2015	2,200	32,000	0.094	9.44	0.000031	MR <sup>1</sup>
	20/05/2015	180	36,000	0.007	0.70	0.000063	MR <sup>2</sup>
	21/07/2015	134	50,000	0.004	0.38	0.000020	MR <sup>2</sup>
	18/08/2015	377	79,000	0.007	0.66	0.000013	MR <sup>2</sup>
	03/11/2015	373	97,000	0.005	0.54	0.000010	MR <sup>2</sup>
	15/12/2015	326	59,000	0.008	0.77	0.000017	MR <sup>2</sup>
	16/02/2016	499	174,000	0.004	0.40	0.000006	MR <sup>2</sup>
	15/03/2016	257	87,000	0.004	0.41	0.000011	MR <sup>2</sup>
	17/05/2016	227	59,000	0.005	0.53	0.000015	MR <sup>2</sup>
	19/07/2016	136	46,000	0.004	0.42	0.000022	MR <sup>2</sup>
	04/10/2016	168	100,000	0.002	0.24	0.000010	MR <sup>2</sup>
	17/01/2017	91	63,000	0.002	0.20	0.000016	MR <sup>2</sup>
	04/04/2017	91	149,000	0.001	0.09	0.000007	MR <sup>3</sup>
	18/07/2017	67	70,000	0.001	0.13	0.000014	MR <sup>2</sup>
	17/10/2017	72	126,000	0.001	0.08	0.000008	MR <sup>3</sup>